Related Experiment Video

Updated: Mar 3, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

10.1K

Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer

Mohammad Hashemi1,2, Shadi Amininia2, Mahboubeh Ebrahimi2

  • 1Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan 98167-43181, Iran.

Oncology Letters
|April 30, 2017
PubMed

Insights

The MDM2 40-bp insertion/deletion polymorphism increases prostate cancer risk in the Iranian population. No significant association was found between TP53 polymorphisms and prostate cancer susceptibility.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Tumor protein 53 (TP53) is a crucial tumor suppressor gene, while Murine double minute-2 (MDM2) is an oncoprotein that inhibits TP53.
  • Polymorphisms in TP53 and MDM2 genes have been investigated for their association with cancer risk, but findings are often inconclusive.
  • Understanding genetic predispositions, like gene polymorphisms, is vital for cancer risk assessment and personalized medicine.

Purpose of the Study:

  • To investigate the association between MDM2 40-bp insertion/deletion (I/D) polymorphism (rs3730485) and TP53 16-bp I/D polymorphism (rs17878362) with prostate cancer (PCa) susceptibility.
  • To evaluate the impact of these specific gene polymorphisms on PCa risk within the Iranian population.

Main Methods:

  • A case-control study was conducted with 103 PCa patients and 142 benign prostatic hyperplasia patients.
  • Genotyping of the MDM2 40-bp I/D and TP53 16-bp I/D polymorphisms was performed using polymerase chain reaction (PCR) analysis.
  • Statistical analysis was employed to determine the odds ratios (OR) and confidence intervals (CI) for PCa risk associated with each genotype.

Main Results:

  • The MDM2 40-bp I/D polymorphism was significantly associated with an increased risk of PCa under a co-dominant model (D/D vs. I/I: OR=1.88, P=0.023).
  • A marginal increase in PCa risk was observed for the MDM2 40-bp I/D polymorphism in a dominant model (I/D+D/D vs. I/I: OR=1.69, P=0.051).
  • No statistically significant association was found between the TP53 16-bp I/D polymorphism and the risk of developing PCa.

Conclusions:

  • The 40-bp I/D polymorphism in the MDM2 promoter region is a risk factor for prostate cancer in the studied Iranian population.
  • The TP53 16-bp I/D polymorphism does not appear to influence prostate cancer susceptibility in this cohort.
  • Further research with larger, diverse ethnic groups is warranted to validate these findings and explore broader implications.
Keywords:
insertion/deletionmurine double minute-2polymorphismprostate cancertumor protein 53

More Related Videos

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

25.1K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
42
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.9K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K